NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 7, 2005 • Volume 2 / Number 23 E-Mail This Document  |  View PDF Version  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
NCAB Approves Redesign of NCI Clinical Trials System

Director's Update
A New Era for Cancer Survivors

Spotlight
Restructuring the NCI Clinical Trials Enterprise

Cancer Research Highlights
Free NRT Program Helps New York City Smokers Quit

Improved Breast Cancer Outcomes Seen with Docetaxel Adjuvant Regimen

Study Finds Breast Cancer Risk with NSAID Use

Mouse Has p53 Tumor Suppressor Gene with On/Off Switch

Mouse Study Suggests Optimal Cells for Immunotherapy

Funding Opportunities

Featured Clinical Trial
Pilot Study of Erlotinib to Treat NSCLC

NCI to Form Translational Research Working Group

Notes
Coleman Awarded ASTRO Gold Medal

NCI Testifies on Radiation Effects from Nuclear Weapons Testing

Cancer Center Profile
Mayo Clinic Cancer Center

Bulletin Archive

Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
PDF Version  View/Print PDF
Featured Article

NCAB Approves Redesign of NCI Clinical Trials System

The National Cancer Advisory Board (NCAB) today formally accepted 22 strategic recommendations designed to reshape and enhance the National Cancer Institute's (NCI) clinical trials system.

The recommendations are included in a report, "Restructuring the National Cancer Institute Clinical Trials Enterprise." The report was developed by the Clinical Trials Working Group (CTWG), a panel of 40 stakeholders established by NCI Director Dr. Andrew C. von Eschenbach in 2004. NCAB's vote to accept the report sets in motion several major steps to implement the recommendations that were first presented to NCAB in February. The result is a series of initiatives that includes an implementation plan and budget.

CTWG Chair Dr. James H. Doroshow, director of NCI's Division of Cancer Treatment and Diagnosis (DCTD), presented the report to NCAB. "With these steps, we hope to integrate the best of NCI's current clinical trial system into a cross-disciplinary enterprise," said Dr. Doroshow. (See Spotlight for a detailed description of the CTWG recommendations or go to http://integratedtrials.nci.nih.gov.)  Read more  

Director's Update

A New Era for Cancer Survivors

The closer we've scrutinized what it means to be a cancer survivor in the United States, the more we've learned about how remarkably complex and daunting an experience it can be. Our intensive study over the past decade has produced excellent data about the risk of second cancers and late effects of treatment, as well as cancer's impact on survivors' emotional and psychological well-being, their ability to maintain or get insurance, their function in the workplace, and even on their relationships with their families and friends.

As former ASCO President and cancer survivor Dr. David Johnson described: With this disease, there is no "Humpty Dumpty moment" during which a patient is reconstructed and simply returns to who he or she was before diagnosis.

But thanks to legions of dedicated advocates and researchers, we have made remarkable strides in elucidating the survivorship experience. And just 2 days ago, many of the more than 10 million cancer survivors in the United States celebrated National Cancer Survivors' Day, embodying all that we've learned about the travails of cancer survivors and how to offer them the individualized support they need and deserve.  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov